Baidu
map

Nat Med:单独atezolizumab或者atezolizumab结合贝伐单抗与舒尼替尼在肾细胞癌中治疗的临床活性和相关分子响应比较研究

2018-06-10 AlexYang MedSci原创

最近,有研究人员阐述了 IMmotion150的研究结果,该研究是一个随机的阶段2研究,具体包括了305名从未治疗过的转移性肾细胞癌患者,并且利用单独的atezolizumab(anti-PD-L1)或者结合贝伐单抗(anti-VEGF)与舒尼替尼治疗结果的比较。主要结果为在意向治疗中的无进展自由生存(PFS)和PD-L1+群体。研究发现,atezolizumab+贝伐单抗或者atezolizum

最近,有研究人员阐述了 IMmotion150的研究结果,该研究是一个随机的阶段2研究,具体包括了305名从未治疗过的转移性肾细胞癌患者,并且利用单独的atezolizumab(anti-PD-L1)或者结合贝伐单抗(anti-VEGF)与舒尼替尼治疗结果的比较。主要结果为在意向治疗中的无进展自由生存(PFS)和PD-L1+群体。

研究发现,atezolizumab+贝伐单抗或者atezolizumab单独治疗与舒尼替尼相比的意向治疗风险比分别为1.0(95%置信区间(CI),0.69-1.45)1.19(95% CI, 0.82-1.71);PD-L1+PFS风险比分别为0.64(95% CI, 0.38-1.08)和1.03((95% CI, 0.63-1.67)。探索生物标志物分析表明了肿瘤变异和肿瘤抗原负担与PFS没有相关性。血管再生、T效应因子/INF-γ响应和粒细胞炎症基因表达特性在治疗过程中与PFS强烈的和差异性的相关。

最后,研究人员指出,这些分子响应情况表明了利用anti-VEGF和免疫治疗对结果进行预测是可能的,并且通过对VEGF的阻断可能克服对免疫检查点阻断的抗性。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1911995, encodeId=42fa191199566, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Feb 19 08:02:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883088, encodeId=654118830881f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 05 09:02:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978698, encodeId=596019e869820, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Oct 04 20:02:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324297, encodeId=3e9f32429e2c, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Jun 15 06:14:21 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477021, encodeId=b20414e7021dd, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Tue Jun 12 10:02:00 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608869, encodeId=18971608869af, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jun 12 10:02:00 CST 2018, time=2018-06-12, status=1, ipAttribution=)]
    2019-02-19 snf701207
  2. [GetPortalCommentsPageByObjectIdResponse(id=1911995, encodeId=42fa191199566, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Feb 19 08:02:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883088, encodeId=654118830881f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 05 09:02:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978698, encodeId=596019e869820, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Oct 04 20:02:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324297, encodeId=3e9f32429e2c, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Jun 15 06:14:21 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477021, encodeId=b20414e7021dd, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Tue Jun 12 10:02:00 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608869, encodeId=18971608869af, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jun 12 10:02:00 CST 2018, time=2018-06-12, status=1, ipAttribution=)]
    2019-05-05 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1911995, encodeId=42fa191199566, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Feb 19 08:02:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883088, encodeId=654118830881f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 05 09:02:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978698, encodeId=596019e869820, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Oct 04 20:02:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324297, encodeId=3e9f32429e2c, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Jun 15 06:14:21 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477021, encodeId=b20414e7021dd, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Tue Jun 12 10:02:00 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608869, encodeId=18971608869af, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jun 12 10:02:00 CST 2018, time=2018-06-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1911995, encodeId=42fa191199566, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Feb 19 08:02:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883088, encodeId=654118830881f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 05 09:02:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978698, encodeId=596019e869820, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Oct 04 20:02:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324297, encodeId=3e9f32429e2c, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Jun 15 06:14:21 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477021, encodeId=b20414e7021dd, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Tue Jun 12 10:02:00 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608869, encodeId=18971608869af, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jun 12 10:02:00 CST 2018, time=2018-06-12, status=1, ipAttribution=)]
    2018-06-15 三生有幸9135

    学习一下谢谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1911995, encodeId=42fa191199566, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Feb 19 08:02:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883088, encodeId=654118830881f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 05 09:02:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978698, encodeId=596019e869820, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Oct 04 20:02:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324297, encodeId=3e9f32429e2c, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Jun 15 06:14:21 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477021, encodeId=b20414e7021dd, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Tue Jun 12 10:02:00 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608869, encodeId=18971608869af, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jun 12 10:02:00 CST 2018, time=2018-06-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1911995, encodeId=42fa191199566, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Feb 19 08:02:00 CST 2019, time=2019-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883088, encodeId=654118830881f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 05 09:02:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978698, encodeId=596019e869820, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Oct 04 20:02:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324297, encodeId=3e9f32429e2c, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Jun 15 06:14:21 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477021, encodeId=b20414e7021dd, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Tue Jun 12 10:02:00 CST 2018, time=2018-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608869, encodeId=18971608869af, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jun 12 10:02:00 CST 2018, time=2018-06-12, status=1, ipAttribution=)]

相关资讯

Cabozantinib与舒尼替尼作为中度或低风险转移性肾细胞癌的最佳治疗方案(Alliance A031203 CABOSUN随机试验):总生存期和无进展生存

随机II期CABOSUN试验比较了cabozantinib和舒尼替尼作为中等或低风险晚期肾细胞癌(RCC)的初始治疗方案,主要终点为符合研究者预期的无进展生存期(PFS)的改善。研究者通过独立的放射学审查委员会(IRC)评估报告PFS、ORR和总体生存期(OS)。先前未经治疗的患有IMDC标准的中度或低风险RCC患者,随机分为1:1至卡唑替尼60 mg / d或舒尼替尼50 mg / d

Sci Rep:静脉癌栓肾细胞癌患者的基因组特性分析

静脉癌栓(VTT)肾细胞癌(RCC)潜在的致死的并发症,但是其潜在的自然发生历史却了解很少。最近,有研究人员观察到静脉血栓包含了数量可观的可视肿瘤细胞,他们利用多区域全外显子组测序手段对37名原发肿瘤和VTT样本,同时包括了来自5名连续性患者的正常组织样本。研究发现,原发肿瘤和VTT之间的变异异质性存在483个相关基因中的106个(22%),这些基因在原发肿瘤或者血栓中要么存在SNVs,要么存在插

NEJM:转移性肾细胞癌患者单纯或肾切除术后舒尼替尼疗效研究

研究发现,对于转移性肾细胞癌患者,舒尼替尼治疗与舒尼替尼联合手术治疗对患者生存期的影响差异不显著

Oncogene:雌激素受体β能够促进肾细胞恶性肿瘤的恶化

之前的研究表明了雌激素受体β(ERβ)能够影响前列腺肿瘤和膀胱肿瘤的恶化,然而,它在肾细胞恶性肿瘤(RCC)中的作用仍旧处于待阐释状态。最近,有研究人员阐释了在RCC患者中,雌激素受体β的表达与总生存/无疾病生存具有负相关关系,并且还提供了相关临床证据。研究人员对机制的剖析阐释了利用雌激素受体β-shRNA以雌激素受体β为靶标和利用17β-雌二醇或者环境内分泌干扰物刺激雌激素受体β的反式激活,均能

盘点:近期肾细胞癌研究进展盘点

肾细胞癌(简称肾癌)是泌尿系统中恶性程度较高的肿瘤,也是最常见的肿瘤之一,又称肾腺癌,占肾恶性肿瘤的80%~90%。据调查,肾细胞癌在我国泌尿生殖系统肿瘤中占第二位,仅次于膀胱肿瘤,占成人恶性肿瘤的2%~3% 、小儿恶性肿瘤的20%左右。男女发病率有明显差异,据统计,男女之比为2:1。肾细胞癌的发病率随年龄增大而升高,有资料显示,肾细胞癌的高发年龄在40~55岁。此外,肾细胞癌发病率有明显的国

Brit J Cancer:转移性肾细胞癌免疫组合治疗后VEGFR TKI治疗效果研究

研究人员发现,那些接受了一线基于免疫的组合疗法(IC)包括免疫检查点抑制剂(CPI)以及接受了随后的系统性治疗的患者的治疗结果到目前仍旧未知。最近,有研究人员对那些患有透明细胞肾细胞癌(mRCC)的连续性病人进行了回顾性分析。研究总共包括了33名患者【平均年龄57岁(37-77),85%为男性,73% ECOG 0】。对那些可以评价的患者(N=28),第一次后续治疗最好的响应为29%具有响应,54

Baidu
map
Baidu
map
Baidu
map